Shares of Apollomics fell sharply Friday in premarket trading after the company said that the third phase bridging trial of its leukemia drug in China didn't meet its endpoints. Shares fell 31% ahead ...
The Options have a term of five (5) years and are exercisable at a price of C$0.205 per common share and will vest over a 24-month period, with one third (1/3 rd) of the Options becoming vested on the ...